v3.26.1
Debt Obligations - Life Sciences Narrative (Details) - USD ($)
 3 Months Ended 12 Months Ended
Aug. 04, 2025
Jan. 31, 2024
Mar. 31, 2025
Dec. 31, 2025
Dec. 31, 2024
Aug. 04, 2024
Jan. 30, 2024
Debt Instrument [Line Items]              
Accrued interest and exit fees (current portion)       $ 72,100,000 $ 61,000,000.0    
Current portion of debt obligations       $ 581,400,000 162,200,000    
R2 Technologies | Lancer Promissory Note | Related Party | Life Sciences              
Debt Instrument [Line Items]              
Optional prepayment, number of days written notice 5 days            
Interest rate 12.00%     12.00%      
Face amount $ 43,500,000            
Short-term debt       $ 47,900,000 24,000,000.0    
Exit fees (non-current portion)         $ 7,900,000    
Interest rate, effective percentage       17.00% 57.80%    
Interest expense, debt       $ 14,700,000 $ 9,800,000    
Interest costs capitalized       5,300,000 6,600,000    
Current portion of debt obligations       46,600,000 31,900,000    
Outstanding debt       47,900,000 $ 24,000,000.0    
Unamortized discount       $ 1,300,000      
R2 Technologies | Senior Notes, Due 2025, 20.00% | Related Party | Life Sciences              
Debt Instrument [Line Items]              
Interest rate   20.00%     20.00%   20.00%
Face amount $ 20,000,000.0 $ 20,000,000.0          
Short-term debt   17,400,000          
Accrued interest and exit fees (current portion)   $ 2,600,000       $ 7,000,000.0  
Exit fees (non-current portion)     $ 16,500,000     $ 16,500,000  
Extension fee percentage 5.00%            
Debt instrument, extension fee $ 2,200,000            
Gains (losses) on restructuring of debt $ 0            
Exit fee percentage   10.50% 13.09%        
Exit fees   $ 2,200,000 $ 8,700,000        
Additional exit fee payable     1,000,000.0        
Increase in exit fee per month     $ 1,000,000.0